Experts say AI-based apps like qXR, which help clinicians diagnose tuberculosis early, could make an enormous impact on the control of the disease in India
Apoorva Mandavilli / New York Times : Tweets: @shashitharoor , @vivnat , @erictopol , @rinachandran , @nythealth , @nythealth , @juneymb , @puneetkdewan , and @paimadhu Tweets: Shashi Tharoor / @shashitharoor : This article, on how AI is transforming TB diagnosis & care in remote hospitals in rural India, is an example of the kind of reporting we never see in the Indian media about our own country, which remains focused on the trivial & sensational: https://www.nytimes.com/... Vivek Natarajan / @vivnat : “If this was to be made available to every X-ray center in rural India, I think we could beat TB” Heartwarming to see AI for medical imaging reach remote Indian districts like Simdega and help fight deadly diseases like TB (by @apoorva_nyc) https://www.nytimes.com/... Eric Topol / @erictopol : Some important progress for #AI in medicine, with caveats https://www.nytimes.com/... by @apoorva_nyc (a break from covid coverage) @qure_ai https://twitter.com/... LongLiveTheRubberDucks / @rinachandran : In rural India and other places where #tuberculosis is rampant, #AI that scans lung X-rays might help eliminate the scourge. https://www.nytimes.com/... @nythealth : “If this was to be made available to every X-ray center in rural India, I think we could beat TB.” https://www.nytimes.com/... @nythealth : In less than a minute, a new app on a phone or a computer can scan an X-ray for signs of tuberculosis, Covid-19 and 27 other conditions https://www.nytimes.com/... Junaid / @juneymb : These Algorithms Could End the Scourge of Tuberculosis - The New York Times https://www.nytimes.com/... Puneet K Dewan / @puneetkdewan : Enormous potential for automated interpretation of CXR for TB screening. Here's the use case: active surveillance. All CXR, public or private, should be shared to the cloud and screened as a part of active TB case finding, with results back to patient./1 https://www.nytimes.com/... Madhu Pai / @paimadhu : Happy to contribute to this nice piece by @apoorva_nyc on the potential for using digital x-rays & AI-based software to screen for TB, Covid-19 & other conditions. Software is no longer the issue. Expensive hardware is what I'm most worried about. https://www.nytimes.com/...
Context & Ripple Effects
Qure.ai's qXR is the chest-scan product behind the Mumbai startup's $16M raise led by Sequoia India in February 2020, and the NYT piece shows it moving from funding round to frontline use: reading X-rays where radiologists are scarce, in rural districts like Simdega. The timing matters — a TB-detection tool arriving during Covid-19, when lung imaging capacity was stretched and TB case-finding was slipping.
The story also lands against a cautionary backdrop: earlier coverage of Google's mammography work warned that AI readers can amplify overtesting and overdiagnosis, a critique that applies directly to any population-scale screening tool.
First-order effects
- Clinicians in radiologist-short rural hospitals get same-day triage of chest X-rays, shifting TB diagnosis from referral-dependent specialist review to on-site AI-flagged reads.
- Qure.ai converts its Sequoia-backed scan-analysis platform into documented public-health deployment, the reference case it needs for further health-system contracts.
Second-order effects
- Indian TB-control programs and donors evaluating qXR must now weigh the mammogram lesson — mass AI screening can surface abnormalities that lead to overtreatment — pushing procurement toward validated specificity thresholds, not just sensitivity claims.
- Rival diagnostic-AI vendors targeting emerging markets face a bar set by an in-country competitor with government-visible deployments, pressuring them toward similar rural-first distribution rather than hospital-premium positioning.
Third-order effects
- If qXR-style tools hold up at scale, diagnostic AI's commercial path runs through radiologist-scarce health systems first, inverting the usual rich-market-first adoption curve and making national TB and screening programs the de facto regulators of these tools' accuracy standards.
The trend: Diagnostic AI is finding its earliest large-scale footing in disease-control programs across radiologist-scarce markets, where distribution reach matters more than premium clinical settings.